Wall Street Analysts See a 33.38% Upside in LifeStance Health (LFST): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 33.4% in LifeStance Health (LFST). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
LifeStance Health Group, Inc. (LFST) Q3 2025 Earnings Call Transcript
LifeStance Health Group, Inc. ( LFST ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Monica Prokocki - Vice President of Investor Relations David Bourdon - CEO & Director Ryan McGroarty - CFO & Treasurer Conference Call Participants Craig Hettenbach - Morgan Stanley, Research Division Lisa Gill - JPMorgan Chase & Co, Research Division Matthew Mardula Brian Tanquilut - Jefferies LLC, Research Division Richard Close - Canaccord Genuity Corp., Research Division Kevin Caliendo - UBS Investment Bank, Research Division David Larsen - BTIG, LLC, Research Division Steven Dechert - KeyBanc Capital Markets Inc., Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. My name is Colby, and I'll be your conference operator today.
LifeStance Health Group (LFST) Reports Break-Even Earnings for Q3
LifeStance Health Group (LFST) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.02 per share a year ago.
All You Need to Know About LifeStance Health (LFST) Rating Upgrade to Strong Buy
LifeStance Health (LFST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
LifeStance Health Group, Inc. (LFST) Q2 2025 Earnings Call Transcript
LifeStance Health Group, Inc. (NASDAQ:LFST ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants David Patrick Bourdon - CEO & Director Monica Prokocki - Vice President of Investor Relations Ryan Bruce McGroarty - CFO & Treasurer Conference Call Participants Brian Gil Tanquilut - Jefferies LLC, Research Division Craig Matthew Hettenbach - Morgan Stanley, Research Division David Michael Larsen - BTIG, LLC, Research Division Jamie Aaron Perse - Goldman Sachs Group, Inc., Research Division Kevin Caliendo - UBS Investment Bank, Research Division Lisa Christine Gill - JPMorgan Chase & Co, Research Division Matthew Mardula - Unidentified Company Richard Collamer Close - Canaccord Genuity Corp., Research Division Steven Craig Dechert - KeyBanc Capital Markets Inc., Research Division Operator Hello, and welcome to the LifeStance Health Second Quarter 2025 Earnings Conference Call. [Operator Instructions] Now I would like to turn the call over to Monica Prokocki.
LifeStance Health Group (LFST) Reports Q2 Loss, Tops Revenue Estimates
LifeStance Health Group (LFST) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.06 per share a year ago.
LifeStance: First Profit, Expanding Margins, And Hybrid Model Make It A Buy Despite Valuation Concerns
LifeStance Health is showing a real turnaround, posting its first-ever net profit and rapidly expanding margins, signaling operational discipline and scalable growth. The company's hybrid care model positions it well amid surging mental health demand, with strong revenue and clinician growth supporting its bullish outlook. Despite a mixed valuation and recent insider selling, institutional investors are accumulating shares, reflecting confidence in LifeStance's long-term margin expansion and platform potential.
LifeStance Health (LFST) Upgraded to Strong Buy: What Does It Mean for the Stock?
LifeStance Health (LFST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
After Plunging 9.9% in 4 Weeks, Here's Why the Trend Might Reverse for LifeStance Health (LFST)
The heavy selling pressure might have exhausted for LifeStance Health (LFST) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Wall Street Analysts Think LifeStance Health (LFST) Could Surge 45.04%: Read This Before Placing a Bet
The consensus price target hints at a 45% upside potential for LifeStance Health (LFST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
LifeStance Health Group, Inc. (LFST) Q1 2025 Earnings Call Transcript
LifeStance Health Group, Inc. (NASDAQ:LFST ) Q1 2025 Results Conference Call May 7, 2025 8:30 AM ET Company Participants Monica Prokocki - VP, IR Ryan McGroarty - CFO David Bourdon - CEO Conference Call Participants Craig Hettenbach - Morgan Stanley Jamie Perse - Goldman Sachs Ryan Daniels - William Blair Brian Tanquilut - Jefferies Richard Close - Canaccord Genuity Dylan Christopher - UBS Steven Dechert - KeyBanc Capital Markets Operator Good day, everyone, and thank you for standing by. My name is Arji, and I will be your conference operator today.
LifeStance Health (LFST) Upgraded to Strong Buy: Here's Why
LifeStance Health (LFST) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
